PALI
PALISADE BIO, INC.
NASDAQ · Healthcare · Biotechnology · US
$1.34
−4.96%1
Insider buys (3m)
0
Insider sells (3m)
$14.2K
Net value (3m)
-28.5%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Oct 7, 2026 | Finley John David · director, officer: CEO CFO | F-InKind | 1,411,982 | $1.49 |
| Oct 7, 2026 | Finley John David · director, officer: CEO CFO | M-Exempt | 3,227,384 | $0.00 |
| Oct 7, 2026 | Finley John David · director, officer: CEO CFO | M-Exempt | 3,059,800 | $0.00 |
| Oct 7, 2026 | Finley John David · director, officer: CEO CFO | M-Exempt | 167,584 | $0.00 |
| Oct 7, 2026 | Jones Mitchell Lawrence · officer: See Remarks | M-Exempt | 2,555,266 | $0.00 |
| Oct 7, 2026 | Jones Mitchell Lawrence · officer: See Remarks | M-Exempt | 65,584 | $0.00 |
| Oct 7, 2026 | Jones Mitchell Lawrence · officer: See Remarks | M-Exempt | 2,620,850 | $0.00 |
| Oct 7, 2026 | Jones Mitchell Lawrence · officer: See Remarks | F-InKind | 1,031,102 | $1.49 |
| Oct 5, 2026 | Williams Donald Allen · director | Purchase | 10,000 | $1.42 |
| Jul 10, 2026 | Baltera Robert Jr. · director | Purchase | 25,000 | $1.96 |
| Jul 10, 2026 | Baltera Robert Jr. · director | Purchase | 20,000 | $1.99 |
| Jul 8, 2026 | Finley John David · director, officer: CEO, CFO | M-Exempt | 133 | $0.70 |
| Jul 8, 2026 | Jones Mitchell Lawrence · officer: Chief Medical Officer | Sale | 51,880 | $2.05 |
| Jul 8, 2026 | Finley John David · director, officer: CEO, CFO | Sale | 146,798 | $2.07 |
| Jul 8, 2026 | Finley John David · director, officer: CEO, CFO | M-Exempt | 335,167 | $0.00 |
| Jul 8, 2026 | Baltera Robert Jr. · director | Purchase | 30,000 | $2.03 |
| Jul 8, 2026 | Baltera Robert Jr. · director | Purchase | 20,000 | $2.05 |
| Jul 8, 2026 | Jones Mitchell Lawrence · officer: Chief Medical Officer | M-Exempt | 131,167 | $0.00 |
| Jul 6, 2026 | Baltera Robert Jr. · director | Purchase | 10,000 | $1.98 |
| Jul 6, 2026 | Baltera Robert Jr. · director | Purchase | 20,000 | $1.98 |
| Jun 18, 2026 | Baltera Robert Jr. · director | A-Award | 336,904 | $0.00 |
| Jun 12, 2026 | Chuang Emil · director | A-Award | 592,300 | $0.00 |
| Jun 12, 2026 | Chuang Emil · director | M-Exempt | 20,200 | $0.00 |
| Jun 12, 2026 | Zwick Jordan Michael · director | A-Award | 336,904 | $0.00 |
| Jun 12, 2026 | Wei Binxian · director | M-Exempt | 20,200 | $0.00 |
| Jun 12, 2026 | Williams Donald Allen · director | A-Award | 1,498,900 | $0.00 |
| Jun 12, 2026 | Wei Binxian · director | A-Award | 592,300 | $0.00 |
| Jun 12, 2026 | Williams Donald Allen · director | M-Exempt | 60,666 | $0.00 |
| Feb 13, 2026 | Finley John David · director, officer: CEO, CFO | M-Exempt | 13,333 | $0.00 |
| Feb 13, 2026 | Jones Mitchell Lawrence · officer: Chief Medical Officer | Sale | 1,989 | $1.75 |
Institutional positioning
13F filings over the trailing two quarters
New 81Increased 60Reduced 52Sold out 26
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Soleus Capital Management, L.P. | New Position | 13,063,687 | Aug 11, 2026 |
| AMERIPRISE FINANCIAL INC | Increased | 11,510,320 | Jul 17, 2026 |
| B Group, Inc. | Unchanged | 11,414,285 | Aug 14, 2026 |
| B GROUP, INC. | Increased | 11,414,285 | May 15, 2026 |
| AMERIPRISE FINANCIAL INC | Reduced | 11,081,434 | Aug 14, 2026 |
| JANUS HENDERSON GROUP PLC | Increased | 10,689,452 | May 18, 2026 |
| Jupiter Topco LLC | New Position | 10,689,452 | Aug 14, 2026 |
| BlackRock, Inc. | Increased | 10,436,760 | Aug 7, 2026 |
| OCTAGON CAPITAL ADVISORS LP | Increased | 10,276,317 | May 15, 2026 |
| Octagon Capital Advisors LP | Unchanged | 10,276,317 | Aug 14, 2026 |
| PERCEPTIVE ADVISORS LLC | Reduced | 8,928,149 | May 29, 2026 |
| PERCEPTIVE ADVISORS LLC | Reduced | 8,425,065 | Aug 14, 2026 |
| COMMODORE CAPITAL LP | Reduced | 7,181,062 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 7,124,116 | May 15, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | Unchanged | 7,124,116 | Aug 14, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Oct 7, 2026